Open AccessPractical Use of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Primary Care
Author(s) -
Timothy Reid
Publication year - 2013
Publication title -
clinical diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.931
H-Index - 37
eISSN - 1945-4953
pISSN - 0891-8929
DOI - 10.2337/diaclin.31.4.148
Subject(s) - agonist , medicine , glucagon like peptide 1 receptor , primary care , receptor , glucagon like peptide 1 , type 2 diabetes , diabetes mellitus , pharmacology , endocrinology , family medicine
IN BRIEF The glucagon-like peptide-1 (GLP-1) receptor agonist class of medications has distinct benefits and limitations that provide an opportunity to individualize the treatment of patients with type 2 diabetes. Many strategies can be used to improve patient acceptance of and self-management with a GLP-1 receptor agonist.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom